Centiva Capital’s Aerie Pharmaceuticals AERI Stock Holding History

Centiva Capital’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-50,000	Closed	-$757K	–	1849
2022 Q3	$757K	Buy	+50,000	New	+$581K	0.01%	733
2022 Q1	–	Sell	-21,936	Closed	-$154K	–	1945
2021 Q4	$154K	Buy	+21,936	New	+$230K	﹤0.01%	1025
2020 Q3	–	Sell	-11,125	Closed	-$164K	–	919
2020 Q2	$164K	Sell	11,125 -863	-7%	-$12.8K	0.01%	547
2020 Q1	$162K	Buy	+11,988	New	+$227K	0.01%	458
2019 Q4	–	Sell	-16,304	Closed	-$313K	–	959
2019 Q3	$313K	Buy	+16,304	New	+$374K	0.02%	431

Centiva Capital's AERI Position: Q4 2022 in Review

Centiva Capital sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 50,000 shares — an estimated $757K sold.

Centiva Capital first reported a position in AERI in Q3 2019 and held it in 5 quarters. The position peaked at $757K in Q3 2022. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.

Centiva Capital reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Centiva Capital sold 50,000 Aerie Pharmaceuticals shares in Q4 2022, an estimated $757K.
Centiva Capital first reported a position in Aerie Pharmaceuticals in Q3 2019 and held it in 5 quarters.
Centiva Capital's Aerie Pharmaceuticals position peaked at $757K in Q3 2022.
0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.

Based on Centiva Capital's 13F filing for Q4 2022, filed 14 Feb 2023.